生长分化因子15(GDF15)预测接受放化疗的不可切除局部晚期非小细胞肺癌的无复发生存和总生存
在OCOG-ALMERA II期随机试验中,分析不可切除局部晚期非小细胞肺癌患者血浆GDF15水平。基线GDF15升高,同步放化疗期间进一步升高,加用二甲双胍后第6周进一步升高。基线GDF15与放疗GTV相关,多因素分析中基线GDF15是不良无复发生存和总生存的预后因素。
要点
- 基线血浆GDF15在患者中升高,同步放化疗期间显著升高(p < 0.001)。
- 加用二甲双胍与第6周GDF15进一步升高相关(p = 0.033)。
- 基线GDF15与放疗大体肿瘤体积(GTV)相关(p < 0.01),多因素分析中基线GDF15是不良RFS和OS的预后因素(p = 0.005和p = 0.002)。
核心结论
- GDF15是响应不可切除局部晚期非小细胞肺癌同步放化疗和二甲双胍治疗的血浆标志物,其水平与肿瘤体积对应,升高预测不良无复发生存和总生存,结果需在更大临床试验数据集中验证。
研究设计与样本
- OCOG-ALMERA(NCT02115464)II期随机临床试验,患者随机接受铂类化疗和胸部放疗(60-66 Gy)联合或不联合二甲双胍(2000 mg/d),在基线、治疗期间(第1周和第6周)及同步放化疗后6个月采集血浆,用ELISA法检测GDF15。
主要发现
- 基线血浆GDF15在研究患者中升高,同步放化疗期间升高(p < 0.001),加用二甲双胍与第6周进一步升高相关(p = 0.033)。
- 基线GDF15水平与放疗大体肿瘤体积(GTV)相关(p < 0.01),放疗第1周GDF15水平与放疗计划靶体积(PTV)相关(p < 0.006)。
- 多因素分析中,基线血浆GDF15是不良无复发生存(p = 0.005)和总生存(p = 0.002)的预后因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些结果需要在更大的临床试验数据集中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Growth differentiation factor 15 (GDF15) is a cytokine of the TGFβ family. Here, we analyzed GDF15 levels in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who participated in OCOG-ALMERA (NCT02115464), a phase II randomized clinical trial, that investigated metformin in combination with standard of care concurrent chemoradiotherapy (cCRT). OCOG-ALMERA was not able to demonstrate benefit in the metformin arm. Therefore, biomarker studies are needed to better define stratification parameters for future trials. METHODS: Patients were randomized to treatment with platinum-based chemotherapy and concurrent chest radiotherapy (60-66 Gy), with or without metformin (2000 mg/d). The trial collected tumor volume parameters, survival outcomes, and patient blood plasma at baseline, during (weeks 1 and 6) and 6 months after cCRT. Plasma GDF15 levels were assayed with the ELISA method. Statistical analyses explored associations between GDF15, survival outcomes, and radiotherapy tumor volumes. RESULTS: Baseline plasma levels of GDF15 were elevated in study patients, they increased during cCRT (p < 0.001), and the addition of metformin was associated with a further increase (week 6, p = 0.033). Baseline GDF15 levels correlated with the radiotherapy gross target volume (GTV, p < 0.01), while week 1 of radiotherapy levels correlated with radiotherapy planned target volume (PTV, p < 0.006). In multivariate analysis, baseline plasma GDF15 was prognostic for poor relapse-free (RFS) and overall survival (OS) (p = 0.005 and p = 0.002, respectively). CONCLUSIONS: GDF15 is a plasma marker that responds to the treatment of unresected LA-NSCLC with cCRT and metformin. GDF15 levels correspond with tumor volume and increased GDF15 levels predict for poor RFS and OS. These results require validation in larger clinical trial datasets.
引用
- Di Pastena F, Pond G, Tsakiridis EE, et al. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy. Radiat Oncol. 2024. PMID: 39511611. doi:10.1186/s13014-024-02546-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。